Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1981 1
1983 1
1985 2
1987 1
1998 1
2001 1
2004 1
2006 2
2007 1
2008 1
2009 2
2010 1
2011 4
2012 3
2013 2
2014 3
2015 1
2016 3
2017 3
2018 1
2020 1
2021 2
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

34 results
Results by year
Filters applied: . Clear all
Page 1
A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma.
Berenson JR, To J, Spektor TM, Martinez D, Turner C, Sanchez A, Ghermezi M, Eades BM, Swift RA, Schwartz G, Eshaghian S, Stampleman L, Moss RA, Lim S, Vescio R. Berenson JR, et al. Among authors: swift ra. Clin Cancer Res. 2020 May 15;26(10):2346-2353. doi: 10.1158/1078-0432.CCR-19-1899. Epub 2020 Jan 14. Clin Cancer Res. 2020. PMID: 31937615 Free article. Clinical Trial.
A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma.
Yashar D, Spektor TM, Martinez D, Ghermezi M, Swift RA, Eades B, Schwartz G, Eshaghian S, Lim S, Vescio R, Berenson JR. Yashar D, et al. Among authors: swift ra. Leuk Lymphoma. 2021 Nov 24:1-9. doi: 10.1080/10428194.2021.2005044. Online ahead of print. Leuk Lymphoma. 2021. PMID: 34818965
Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.
Vidisheva AP, Wang J, Spektor TM, Bitran JD, Lutzky J, Tabbara IA, Ye JZ, Ailawadhi S, Stampleman LV, Steis RG, Moezi MM, Swift RA, Maluso TM, Udd KA, Eshaghian S, Nassir Y, Berenson JR. Vidisheva AP, et al. Among authors: swift ra. Support Care Cancer. 2017 Oct;25(10):3217-3224. doi: 10.1007/s00520-017-3732-6. Epub 2017 Apr 28. Support Care Cancer. 2017. PMID: 28455546
Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients.
Ghermezi M, Li M, Vardanyan S, Harutyunyan NM, Gottlieb J, Berenson A, Spektor TM, Andreu-Vieyra C, Petraki S, Sanchez E, Udd K, Wang CS, Swift RA, Chen H, Berenson JR. Ghermezi M, et al. Among authors: swift ra. Haematologica. 2017 Apr;102(4):785-795. doi: 10.3324/haematol.2016.150896. Epub 2016 Dec 29. Haematologica. 2017. PMID: 28034989 Free PMC article.
Risk of skin cancer in multiple myeloma patients: a retrospective cohort study.
Robinson AA, Wang J, Vardanyan S, Madden EK, Hebroni F, Udd KA, Spektor TM, Nosrati JD, Kitto AZ, Zahab M, Cheema S, Fors DH, Norberg A, Diehl J, Waterman GN, Swift RA, Crowley J, Berenson JR. Robinson AA, et al. Among authors: swift ra. Eur J Haematol. 2016 Nov;97(5):439-444. doi: 10.1111/ejh.12748. Epub 2016 Mar 7. Eur J Haematol. 2016. PMID: 26872804
Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.
Cohen A, Spektor TM, Stampleman L, Bessudo A, Rosen PJ, Klein LM, Woliver T, Flam M, Eshaghian S, Nassir Y, Maluso T, Swift RA, Vescio R, Berenson JR. Cohen A, et al. Among authors: swift ra. Br J Haematol. 2018 Jan;180(1):60-70. doi: 10.1111/bjh.14992. Epub 2017 Nov 21. Br J Haematol. 2018. PMID: 29164606 Clinical Trial.
34 results